Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

Stifel Nicolaus analyst Adam Borg maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $200.00. The company’s shares opened today at $194.57. Borg covers the ...

In a report released today, Jason Celino from KeyBanc maintained a Buy rating on PTC (PTC – Research Report). The company’s shares closed yesterday at $198.04. Celino covers the Technology ...

ROKA -13%.Now read: AcelRx: Ironically, I Misunderstood The... BySeeking Alpha • Sep 26, 2017 Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14 ...

For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...

Baird analyst Joe Vruwink raised the firm’s price target on PTC (PTC) to $228 from $226 and keeps an Outperform rating on the shares. The firm said management was very forceful that disruption ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $106.7 million in its third quarter. The Warren, New Jersey-based company said it had a loss ...

PTC Therapeutics (NASDAQ:PTCT) shares plunged more than 22% after-hours following topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich... After-Hours Stock Movers: PTC ...

PTC Forecasts Quarterly Revenue Below Estimates on Tight Tech Spending (Reuters) - Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued ...